Tokyo, Japan

Takao Ando


Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 238(Granted Patents)


Location History:

  • Tokyo, JA (1976 - 1977)
  • Nerima, JP (1984 - 1987)
  • Kodaira, JP (1988)
  • Setagaya, JP (1987 - 1989)
  • Tokyo, JP (1979 - 1997)
  • Yamanashi, JP (1996 - 2001)

Company Filing History:


Years Active: 1976-2001

Loading Chart...
48 patents (USPTO):

Title: Innovations by Takao Ando: A Journey Through Patents and Collaborations

Introduction

Takao Ando, based in Tokyo, Japan, has made significant contributions to the field of biotechnology, particularly in the development of therapeutic compounds. With an impressive portfolio of 48 patents, Ando's inventions focus on addressing critical health challenges through innovative oligonucleotide and antibody-based treatments. This article explores his latest patents, career highlights, and collaborations with notable colleagues.

Latest Patents

Among Takao Ando's most recent innovations is the development of oligonucleotide inhibitors of PAI-1 mRNA. This invention includes oligonucleotides with specific sequences designed to create pharmaceutical compositions that can treat or prevent diseases related to extracellular matrix deposition. Additionally, his patent for an immunoglobulin Fc fragment bound to an alkylating, antibiotic, or antimetabolic antitumor substance represents a breakthrough in cancer therapy. This composition ensures that the Fc fragment remains stable in the body, allowing for prolonged activity of the attached antitumor substances.

Career Highlights

Throughout his career, Takao Ando has worked with prominent companies in the chemical and pharmaceutical sectors, including Kureha Kagaku Kogyo Kabushiki Kaisha and Kureha Chemical Industry Company, Limited. His work has been instrumental in bridging the gap between innovative research and practical applications in medicine, contributing to advancements in treatments that improve patient outcomes.

Collaborations

Ando has collaborated with esteemed colleagues, such as Chikao Yoshikumi and Takayoshi Fujii. Their teamwork has fostered a rich environment for innovation and has led to several patented compounds that hold promise for various therapeutic applications. Their collective efforts underscore the importance of collaboration in the field of biotechnology and pharmaceutical research.

Conclusion

Takao Ando's extensive patent portfolio and collaborative efforts reflect his dedication to advancing medical science through innovation. His latest inventions demonstrate the potential to significantly impact the treatment of diseases, particularly in the realm of oncology and chronic conditions. As he continues to pave the way for new therapeutic strategies, Ando's work remains pivotal in the ever-evolving landscape of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…